Field‑Directed 5‑Fluorouracil for Extensive Actinic Keratoses

Evidence and Guideline Recommendation

• The American Academy of Dermatology (2021) gives a strong recommendation (moderate‑quality evidence) for using topical 5‑fluorouracil as field therapy in patients with extensive actinic keratoses. 1, 3

Rationale for Field‑Directed Therapy

• Field cancerization is characterized by multiple rough, scaly patches with erythematous bases across contiguous sun‑exposed areas, often with a “sandpaper” texture on the dorsal forearms. Treating the whole field addresses both visible and subclinical lesions. Strong recommendation (moderate evidence). 1
• Field‑directed treatment reduces the risk of new actinic keratoses by targeting underlying UV‑induced DNA damage. Strong recommendation (moderate evidence). 1, 2

Dosing and Application of 5‑Fluorouracil

• Regimen: Apply 0.5 % cream once daily for 2–4 weeks to all affected areas; for thicker lesions, 5 % cream may be applied twice daily for the same duration. Flexible dosing based on tolerance. 3, 4
• Cost: 5‑fluorouracil is widely available and less expensive than newer topical agents, supporting its cost‑effectiveness. Strong recommendation (moderate evidence). 5

Efficacy Compared with Other Topicals

• Hazard ratios for treatment failure versus 5‑fluorouracil: imiquimod = 2.03, photodynamic therapy = 2.73, ingenol mebutate = 3.33 (all P ≤ 0.001). Strong recommendation (moderate evidence). 3, 4

Management of Expected Local Reactions

• Common reactions—erythema, crusting, soreness—are indicative of therapeutic effect and should be explained to patients. Strong recommendation (moderate evidence). 6, 5
• If reactions become excessive, reduce application frequency or insert short treatment breaks to improve tolerability. Conditional recommendation (moderate evidence). 5
• Approximately 50 % of patients discontinue treatment early (≈6 weeks) because lesions appear resolved; completing the full course significantly lowers recurrence risk. Strong recommendation (moderate evidence). 7, 6

Alternative Topical: Imiquimod

• Imiquimod 5 % cream receives a strong recommendation (moderate‑quality evidence) for field therapy when 5‑fluorouracil is unsuitable. 1, 3
• Regimen: Apply three times weekly for 4 weeks; a second 4‑week course may be added if needed. Strong recommendation (moderate evidence). 7, 6
• Efficacy: Approximately 50 % complete clearance; long‑term maintenance shows 76 % clearance at 12 months versus 33 % with 5‑fluorouracil (methodological limitations noted). Conditional recommendation (moderate evidence). 7, 6

Role of Cryosurgery

• Cryosurgery is strongly recommended for individual lesions but impractical as monotherapy for extensive disease due to time, pain, and lower effectiveness in preventing new lesions. Strong recommendation (moderate evidence). 1, 2, 3
• Combination strategy: Use cryosurgery for thick or treatment‑resistant lesions after completing field therapy. Conditional recommendation (moderate evidence). 1, 3

Special Populations & Observation

• In patients with limited life expectancy, observation may be reasonable when treatment morbidity outweighs benefits, but field therapy remains appropriate for symptomatic lesions and to lower SCC risk. Conditional recommendation (moderate evidence). 1, 2, 4
• Actinic keratoses can cause pruritus and tenderness, and each lesion carries a low but real risk of progression to squamous cell carcinoma. Strong recommendation (moderate evidence). 1, 8, 2
• Field therapy can be completed in 2–4 weeks with manageable side effects, supporting its use even in elderly patients. Strong recommendation (moderate evidence). 6, 5

Prevention, Surveillance, and Recurrence Management

• UV protection is a good‑practice statement endorsed by the American Academy of Dermatology. Strong recommendation (expert opinion). 1, 2, 3
• Recurrence is common, occurring in up to 50 % of patients within the first year after treatment. Strong recommendation (moderate evidence). 1, 2
• Repeat field treatment should be considered for new lesions or recurrence. Conditional recommendation (moderate evidence). 6, 5
• Ongoing surveillance for squamous cell carcinoma in previously treated areas is advised. Strong recommendation (moderate evidence). 2, 8

Treatments to Deprioritize

• Diclofenac gel carries a conditional recommendation with low‑quality evidence and is less effective than 5‑fluorouracil or imiquimod. Conditional recommendation (low evidence). 1, 3
• Photodynamic therapy is conditionally recommended but is more costly, requires office visits, and shows inferior long‑term efficacy compared with 5‑fluorouracil. Conditional recommendation (moderate evidence). 1, 3

Common Pitfalls & Practical Tips

• Inadequate counseling about expected erythema and crusting leads to premature discontinuation; clear patient education is essential. Strong recommendation (moderate evidence). 6, 5
• Treating only visible lesions misses subclinical disease; field therapy reduces future lesion development. Strong recommendation (moderate evidence). 1, 2
• Caution on poor‑healing sites (e.g., lower legs); the scalp, face, and arms generally heal well, making them suitable for 5‑fluorouracil. Conditional recommendation (moderate evidence). 6, 5